Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

¿Te ayudamos?

Ejemplos de búsqueda

Vídeos Explicativos

Enhanced-DDS

Financiado

Cerrado

An enhanced drug delivery system for brain cancer treatment which will be tested...

An enhanced drug delivery system for brain cancer treatment which will be tested by human cell-based 3D in vitro microfluidic system Cancer treatment by current clinical methods has many side effects, which result from the non-specificity of these methods. Moreover, treatment of some cancers, such as brain tumors, is extremely difficult because the brain barrie... ver más

30/06/2025

SABANCI UNIVERSITY

148K€

Presupuesto del proyecto: 148K€

Líder del proyecto

SABANCI UNIVERSITESI No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Fecha límite participación Sin fecha límite de participación.

Financiación concedida El organismo HORIZON EUROPE notifico la concesión del proyecto el día 2025-06-30

HORIZON-MSCA-2022-PF-01-01: MSCA Postdoctoral Fellowships 2022 Expected Outcome:

I+D

Cerrada

0% 100% 100%

Características del participante

Este proyecto no cuenta con búsquedas de partenariado abiertas en este momento.

Información adicional privada

No hay información privada compartida para este proyecto. Habla con el coordinador.

1 Participantes

SABANCI UNIVERSITY

148.48K€ | Lider

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Duración del proyecto: 26 meses Fecha Inicio: 2023-04-27
Fecha Fin: 2025-06-30

Líder del proyecto

SABANCI UNIVERSITESI No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Presupuesto del proyecto 148K€

Fecha límite de participación Sin fecha límite de participación.

Descripción del proyecto Cancer treatment by current clinical methods has many side effects, which result from the non-specificity of these methods. Moreover, treatment of some cancers, such as brain tumors, is extremely difficult because the brain barriers (blood-brain barrier (BBB) and blood tumor barrier (BTB)) prevents more than 98% of drugs from entering the brain. The use of stimuli-responsive nanomaterials for cancer therapy is more efficient than conventional ones due to access to targeting tissues, deep molecular targets, lower side effects, and controlled drug release. Mesoporous silica nanoparticles (MSNs) are widely used nanocarrier for drug delivery due to their unique physicochemical properties. However, the lack of consideration of the economic efficiency of MSNs synthesis, their surface modification methods, and the lack of use of physiologically relevant systems to test the efficacy and safety of MSNs, have caused that an effective and definitive cancer treatment method by MSNs has not been provided so far. In this project we aim to solve these problems and make the use of MSNs for therapeutic approaches realistic. The goal of this project is to develop a biosource-derived stimuli-responsive MSN for combined PDT/ chemotherapy of brain tumors to be evaluated in a physiologically relevant human cell-based 3D in vitro brain tumor microfluidic system. This project will be the first to investigate a combination therapeutic agent based on natural products modified with advanced plasma technology and evaluated in a novel human cell-based 3D microfluidic in vitro system that includes the BBB. Outcomes of this project will enhance the existing knowledge and technologies for MSNs’ synthesis, modification, and their cancer treatment performance evaluation, which will yield high-impact journal publications, as well as potential commercial product in the long term.

Conecta tu I+D

Entra hoy

Forgot your password?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores